Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World

• Published in: OncoTargets and therapy Vol. 13; pp. 143 - 149
• Main Authors: Cui, Hanzhi, Dai, Guanghai, Guan, Jingzhi
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2020; Dove
• Subjects: Antineoplastic agents; Apoptosis; Avelumab; Biochemistry; Cabozantinib; Cancer; Carcinoma; Cell death; Cemiplimab; Clinical trials; Development and progression; Diseases; Drug therapy; Durvalumab; Health aspects; Hepatitis B; Hepatitis C virus; Hepatocellular carcinoma; Immunotherapy; Infection; Ipilimumab; Lenvatinib; Nivolumab; Original Research; Pembrolizumab; Ramucirumab; Regorafenib; Sorafenib; Tumors; China; immune checkpoint inhibitor; adverse events; hepatocellular carcinoma; programmed cell death protein-1-targeted immunotherapy
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S234868

Hepatocellular carcinoma (HCC) is one of the most common malignant solid tumors. Its incidence is increasing worldwide due to the dissemination of hepatitis B infection, HCV infection and nonalcoholic steatohepatitis-related HCC. For patients with advanced HCC, the available treatments are extremely...